Molecular and Computational Methods for the Detection of Microsatellite Instability in Cancer

Laura G. Baudrin 1,2, Jean-François Deleuze 1,3 and Alexandre How-Kit 1 *

1 Laboratoire de Génomique, Fondation Jean Dausset–CEPH, Paris, France, 2 Laboratoire d’Excellence GenMed Paris, Paris, France, 3 Centre National de Recherche en Génomique Humaine, CEA–Institut François Jacob, Evry, France

Microsatellite instability (MSI) is a genomic alteration in which microsatellites, usually of one to four nucleotide repeats, accumulate mutations corresponding to deletions/insertions of a few nucleotides. The MSI phenotype has been extensively characterized in colorectal cancer and is due to a deficiency of the DNA mismatch repair system. MSI has recently been shown to be present in most types of cancer with variable frequencies (from <1 to 30%). It correlates positively to survival outcome and predicts the response to immune checkpoint blockade therapy. The different methods developed for MSI detection in cancer require taking into consideration two critical parameters which influence method performance. First, the microsatellite markers used should be chosen carefully to ensure they are highly sensitive and specific for MSI detection. Second, the analytical method used should be highly resolute to allow clear identification of MSI and of the mutant allele genotype, and should present the lowest limit of detection possible for application in samples with low mutant allele frequency. In this review, we describe all the different molecular and computational methods developed to date for the detection of MSI in cancer, how they have evolved and improved over the years, and their advantages and drawbacks.

Keywords: microsatellite instability, MSI-H cancer, MSI detection method, next-generation sequencing, computational biology, microsatellite genotyping

INTRODUCTION

Microsatellite instability (MSI/MSI-H) is characterized by the accumulation of mutations (insertions or deletions of a few nucleotides) in microsatellites (also known as short tandem repeats), which are continuous repetitions of 1–9 nucleotides. It has been shown that MSI is caused by loss of function of a member of the DNA mismatch repair system (MMR), which normally allows the repair and correction of DNA following DNA mismatches introduced by DNA polymerase (1). The MMR system comprises at least ten proteins including MLH1, MSH2, MSH6, and PMS2, which are the most frequent mutated or epimutated (MLH1) genes in cancer (1–6).

MSI has been described and extensively characterized in colorectal cancer in which 15–20% of tumors present the MSI phenotype which is correlated with better patient survival (7–9). In addition, 3% of MSI colorectal cancers arise in the context of an inherited syndrome called Hereditary Non-Polyposis Colorectal Cancer (HNPPCC) or Lynch syndrome, in which a constitutional mutation of an MMR gene leads to an increased risk of cancer incidence requiring specific management (10–12).
Repair Deficiency (CMMRD) is due to bi-allelic germline mutations of one of the four MMR genes (MLH1, MSH2, MSH6, or PMS2), and is characterized by the appearance of multiple neoplasia including colorectal cancer in childhood (13, 14).

MSI has also been detected in other types of cancer including gastric (6), endometrial (5), ovarian (15), and liver (16) cancer, however it is only recently that MSI has been widely identified across several types of cancer through studies based on the analysis of whole genome/exome sequencing data (4, 17, 18). The incidence of MSI in cancer correlates positively to survival outcome (17) and can also predict the efficacy of immune checkpoint blockade therapy in solid tumors (19, 20).

Different approaches have been developed for MSI detection in cancer with the aim of providing the highest degree of sensitivity and specificity. The first parameter influencing the detection of MSI in cancer is the type of microsatellite markers used. Different microsatellites and microsatellite panels have been proposed for sensitive detection of MSI including the Bethesda/NCI panel, which has been the gold standard microsatellite panel for MSI detection for more than 20 years (21–23). This gold standard method relies principally on PCR followed by capillary electrophoresis fragment analysis, whereas other methods also developed to improve the limit of detection (LOD) of MSI, as required for some applications (e.g., to detect MSI in blood and in tumors with a high level of normal cell contamination or in precancerous lesions), rely on the modification of standard procedures (24–26). Recently, with the development of next-generation sequencing (NGS), new computational algorithms have emerged which allow the detection of MSI in thousands of microsatellite markers, a discovery which could change the standard of MSI detection in cancer (27–29).

In this review, we describe the different approaches developed to date for the detection of MSI in cancer, and we highlight and compare the advantages and drawbacks of each method.

**EVOLUTION OF THE STANDARD TECHNOLOGIES FOR MSI DETECTION AND IDENTIFICATION IN CANCER**

Although the methods used for MSI detection in cancer have constantly evolved, they still rely on two constants: (i) the amplification of one or several microsatellite markers with PCR-based methods, and (ii) the detection of MSI by methods which allow fragment length analysis (Figure 1).

MSI detection was initially performed in colorectal cancer either by using PCR on specific markers followed by polyacrylamide gel electrophoresis and autoradiography (7, 30), or a fingerprinting method based on arbitrarily primed PCR (AP-PCR) in which primers with arbitrarily chosen sequences are used in a PCR characterized by a few low stringency cycles followed by several higher stringency cycles, and combined with electrophoresis for fragment separation (9, 31). In some laboratories, MSI detection was performed with silver or ethidium bromide staining of polyacrylamide gel after electrophoresis rather than autoradiography (Figure 1A) (32).

These methods, which proved laborious and time-consuming and presented a low sizing accuracy, were supplanted by a newer approach which remains today the gold standard for MSI detection. This approach combines a PCR with fluorescent primers and capillary electrophoresis using a DNA sequencer which allows fragment analysis at single base resolution (Figure 1B) (33). This procedure has also been improved by the multiplexing of PCR to allow amplification of 2–5 microsatellite markers (34–40) and automatic identification of the allele size (34).

Other read-out methods have also been used for MSI detection following PCR amplification of microsatellite markers, including denaturing high-performance liquid chromatography (DHPCL) (41–43) and high resolution melting (HRM) analysis (44). DHPCL relies on the separation of DNA strands based on the size and sequence, and presents the advantage of being free from stutter peaks (undesirable frameshift products, multiples of the repeated nucleotide sequence, and generally shorter than the specific amplification product, which are formed due to slippage of DNA polymerase during PCR amplification (45)); DHPCL has a limit of detection of 1% of mutated alleles (Figure 1C) (41). In contrast, HRM is a rapid, closed-tube post-PCR method based on the slow denaturation of the PCR products and the differences in the denaturation curves between mutated and wild-type; its drawback is that it allows the detection but not the identification of MSI (Figure 1D) (44).

Recently, massive parallel next-generation sequencing (NGS) has also been used to detect MSI in cancer (4, 17), with a limit of detection evaluated at 1% of MSI in an MSS background (Figure 1E) (46). The great advantage of NGS is that MSI can be simultaneously detected in a large number of microsatellite loci, ranging from five to several hundred thousand depending on the protocol used for library preparation (4, 27, 47). Library preparation is based on the standard procedures for whole genome sequencing (WGS), whole exome sequencing (WES) and targeted gene sequencing (TGS) of gene panels [e.g., ColoSeq, UW-OncoPlex (27), BROCA (3), ColonCore NGS panel (48), and smMIP panel (46)]; this last approach is based either on amplicon sequencing (49), complementary RNA (cRNA) biotinylated oligonucleotide sequence capture (50) or single-molecule molecular inversion probe capture (51). A proof of concept study using ultra-deep sequencing has also been performed using the Bethesda/NCI panel. Five markers were sequenced with a coverage of 5000–8000 x and gave similar results to the gold standard method, thus demonstrating that NGS can be used for MSI testing (47). However, MSI detection by NGS requires the development of specific algorithms and computational methods which will be described later in this review.

**THE CHOICE OF MICROSATELLITE MARKERS IMPROVES THE SENSITIVITY OF MSI DETECTION IN CANCER**

MSI was initially described in 1993 in colorectal cancers in which deletions in several amplicons of mono-, di-, and tri-nucleotide
FIGURE 1 | Overview of the different methods used for MSI detection in cancer: (A) Polyacrylamide gel electrophoresis (PAGE), (B) Capillary electrophoresis fragment analysis (FA), (C) Denaturing high performance liquid chromatography (DHPLC), (D) High resolution melting analysis (HRM), (E) Next-generation sequencing (NGS).
repeats were shown to be present in 12% of the tumors, using an AP-PCR approach (9). The same year, two other studies detected MSI in sporadic (13–28%) and hereditary non-polyposis (79%) CRC, based on PCR and gel electrophoresis using four dinucleotide (CA) microsatellite markers (Mfd 26, Mfd 27, Mfd 41, and 63S/636) (7) or 6 dinucleotide (CA) microsatellite markers (D2S119, D2S123, D2S147, D10S197, D11S904, and D13S175) and one trinucleotide (CTG) microsatellite marker (CTG-B37) (30). The percentage of tumors with MSI, based on each marker taken alone, varied greatly indicating that all microsatellites present different sensitivities for MSI detection as they probably display different stabilities for MMR deficiency (2, 30, 32, 33, 52). Thus, a combination of the most sensitive microsatellite markers should be used for MSI assessment in cancer.

In order to standardize the panel of microsatellites used for MSI detection in cancer across the different laboratories in the world, a National Cancer Institute (NCI) workshop held in Bethesda, (Maryland, USA) proposed a panel of two mononucleotide (BAT-25 and BAT-26) and three dinucleotide (D2S123, D5S346, and D17S250) repeat microsatellites called the Bethesda/NCI panel for the detection of MSI in colorectal cancer, and according to which tumors presenting two or more unstable markers (or ≥30–40% if more markers are tested) should be defined as MSI/MSI-H (21). The other tumors are classified as MSS (microsatellite stable) or MSI-L (MSI-low) if no markers or only one marker is unstable (or <30–40% if more markers are tested) (21). Though still under debate, MSS and MSI-L tumors are usually considered and treated clinically as a single group, and it is generally agreed today that MSS and MSI-L tumors belong to the same group, as most MSS tumors can normally be classified as MSI-L if a sufficient number of microsatellite markers are tested (17, 23, 53–56).

Although the Bethesda/NCI panel is recommended again in the revised Bethesda guidelines for Lynch syndrome and MSI (22), and remains today the gold standard used in several laboratories for MSI detection, several concerns have arisen regarding this panel (57, 58). These concerns notably relate to the presence of dinucleotide markers in the panel, which have a lower ability to detect MSI-H tumors due to their lower sensitivity compared to mononucleotide microsatellites, and they require matched normal samples for MSI detection due to their natural polymorphism in individuals, which can lead to MSS/MSI-L tumors being misclassified as MSI-H (58–63).

Therefore, some researchers have claimed that mononucleotide repeat microsatellites are the most appropriate markers for MSI detection, as they are more sensitive and almost monomorphic, thus requiring less use of mixed normal samples (57, 58, 60, 62, 63). The use of BAT-26, a quasi-monomorphic microsatellite present in Caucasian but not in African populations, has been proposed for MSI detection (with no need to match normal DNA), either on its own (57, 60) or in combination with BAT-25 (64), and has proved effective in large cohort studies (10, 65). In 2002, the same authors proposed a set of five quasi-monomorphic mononucleotide repeat microsatellites (BAT-25, BAT-26, NR-21, NR-22, and NR-24), known as the pentaplex panel, which allow the detection of MSI without matching normal DNA, and offer better performance compared to BAT-26 or BAT-25 alone (35), or compared to the Bethesda panel (66). Most of these markers have been combined in a new mononucleotide repeat pentaplex panel (NR-21, NR-24, BAT-25, BAT-26, and NR-27/MONO-27), optimized for MSI detection based on the screening of 266 mono- to penta-nucleotide repeat microsatellites. This panel has out-performed the current Bethesda panel (36, 37, 63, 67), and is currently marketed as the MSI Analysis System by Promega Corporation (Madison, Wisconsin, USA) and is also considered as a gold standard panel for MSI detection in cancer.

Several other mononucleotide repeat microsatellites have been proposed as sensitive and specific markers for MSI detection in cancer. Among these are CAT-25, a quasi-monomorphic mononucleotide repeat microsatellite in all populations, which has been put forward as a single marker for MSI detection in CRC, offering improved performance compared to the Bethesda panel, BAT-25 or BAT-26 (68, 69). CAT-25 has also been proposed in combination with three mononucleotide repeat microsatellites (BAT26, NR21, and NR27) in a tetraplex panel which allows MSI detection in solid tumors, notably in MSH6-deficient tumors where the pentaplex panel fails at times to detect MSI (38). Another microsatellite, HT-17, has also been proposed as a sole marker for MSI detection in CRC as it presents better sensitivity compared to the pentaplex panel (70, 71). Moreover, HT-17 has been found to carry prognostic and predictive information on the response to chemotherapy (5-FU and oxaliplatin) in CRC patients where large deletions in HT-17 indicate a better prognosis and better response to treatment (70, 72). Recently, a panel of five long mononucleotide repeat microsatellites (BAT-52, BAT-55, BAT-56, BAT-57, and BAT-59), also evaluated for MSI detection in early colorectal lesions, showed improved sensitivity compared to the Bethesda and pentaplex panels (73).

Since the development of NGS, a greater number of microsatellites, and potentially all microsatellites in the genome, can now be analyzed for MSI detection, an advance which could further improve the detection of MSI in cancer. However, two studies based on WGS and WES NGS data have shown that most microsatellites in the genome are stable and therefore would not be informative in the case of MMR deficiency (4, 17). These studies also showed that MSI frequently affects mononucleotide repeat microsatellites, in particular those of 16 repeat units in length as well as microsatellites located in intergenic, intronic, and 3′ UTR regions (4, 17). Both studies demonstrated that some unstable microsatellites were intra- and/or inter-tumor-type specific, and also identified the most frequently recurring unstable microsatellites across all MSI-H cancers, a finding which could further be used to define new pan-cancer panels for MSI detection with improved sensitivity and specificity (4, 17). The development of new specific cancer-type and pan-cancer panels could be useful especially as the microsatellites in the Bethesda and pentaplex panels, which are principally recommended for CRC but used in all types of malignancies, have shown poor performance in other types of cancer (46, 74–76).

To date, most studies on MSI detection in cancer that are based on NGS experiments have either evaluated MSI in several
types of microsatellites (mono- to penta-nucleotide repeat) or refined their analysis to mononucleotide repeat microsatellites using microsatellite sequencing data available on WGS, WES or TGS of panels of genes implicated in cancer which were not initially designed for MSI detection (4, 17, 18, 27, 28, 56). Only three panels recently published are specifically designed for MSI detection in cancer, namely the MSIplus panel which evaluates mutations in 3 oncogenes (KRAS, BRAF, and NRAS) and 17 microsatellites (49), the ColonCore Panel which allows the simultaneous detection of MSI and mutations in 36 CRC-related genes principally proposed for CRC (48), and a pan-cancer panel of 111 microsatellite loci highly informative in cancer (46). These panels have shown either a comparable or better performance for MSI detection in colorectal and non-colorectal cancers than the pentaplex panel (46).

**IMPROVING THE LIMIT OF DETECTION OF MSI IN CANCER THROUGH MODIFICATION OF THE STANDARD PROTOCOL**

Capillary electrophoresis fragment analysis is the standard molecular method for MSI detection in cancer, however this method presents a LOD which might not be sufficient for some clinical applications such as the detection of MSI in blood, plasma, precancerous lesions, and tumors with high levels of normal cell contamination, or in tumor heterogeneity where only a small subset of the tumor cells present MSI. The particularity of the LOD of MSI is that it can vary (from 1 to 10%) according to the length of the mutant alleles and the WT genotype, so that large deletions present a lower LOD than small deletions due to the presence of stutter peaks which mask mutant alleles (26).

Therefore, different approaches which modify a single step of the standard fragment analysis protocol have been developed to improve the LOD of MSI (Figure 2). A first such approach proposed for diagnosis of CMMRD syndrome was based on MSI detection in lymphoblastoid cell lines derived from CMMRD patients rather than in blood, and which had developed ex vivo MSI phenotype during in vitro culture (77). While this method presents a clinical sensitivity and specificity of 100%, the time to result is 120 days after immortalization (77).

Three other methods have been proposed for MSI detection, all of which rely on a pre-PCR modification of the standard procedure. In small-pool PCR, the DNA is diluted so that the PCR is performed on 0–3 genome equivalents, thus allowing the mutated alleles to be easily detected and quantified (Figure 2A) (78–81). This method has allowed MSI detection in non-tumoral colon mucosa, urinary tract epithelial cells, PBL, saliva, and lymphoblastoid cell lines of HNPCC patients, however it requires multiple replicate PCR experiments (at least a hundred PCRs with one genome equivalent for a limit of detection of 1%) (80–82). Nuclease-assisted minor allele enrichment with either probe overlap (NaME-Pro) and nuclease-assisted microsatellite instability enrichment (NaMSIE) are two recently developed methods based on the use of DNA and locked-nucleic-acid(LNA)-containing probes complementary to WT microsatellite sequences, respectively, combined to the preferential digestion of fully matched over mismatch-containing double-stranded DNA by a duplex-specific nuclease (DSN), which leads to the enrichment of mutant alleles prior to PCR (Figure 2B) (24, 83). These methods present a limit of detection of 0.5 and 0.01% of mutant alleles when combined to capillary electrophoresis and HRM, respectively, and greatly improve MSI detection in CRC samples with low tumoral cell content and circulating DNA of plasma samples of CRC patients (24, 83).

One such method proposed to improve MSI detection and derived from a modification of the PCR protocol, is based on E-ice-COLD-PCR, a method previously developed for enrichment of point mutations located in mutual hotspots in oncogenes such as BRAF, NRAS, and KRAS (84–88). This method relies on the use of a non-elongable poly T LNA blocker probe complementary to the WT sequence which hybridizes to the WT and mutant sequence, and on the preferential denaturation of the mutant-probe heteroduplex compared to WT-probe homoduplex at a critical temperature (Tc) to allow a strong enrichment of mutant microsatellite alleles during primer annealing/elongation steps (Figure 2C) (26). E-ice-COLD-PCR lowers the limit of detection of MSI to 0.05% of mutant alleles, allowing MSI detection in 100% of CRC samples with a high level of normal cell contamination, however it requires the use of WT control samples due to the enrichment of stutter peaks during PCR amplification (26).

Finally, a post-PCR method called gMSI has been developed to improve the sensitivity of MSI detection in blood from CMMRD patients. This method relies on the analysis of the height of n+1 and n+2 stutter peaks compared to the n peak (where n is the size of the WT allele) and uses freely available software (25). Although gMSI is more sensitive than the standard method, it is unable to detect MSI due to MSH6 deficiency (77).

**COMPUTATIONAL METHODS FOR MSI DETECTION IN CANCER**

Before the advent of NGS, to our knowledge only two mathematical prediction models had been developed for MSI detection in colorectal and gastric cancers. These models used six and seven microsatellites (mono- and di-nucleotide repeat), respectively, and were based on a two-population (MSI vs. MSS) model in which the binomial distributions mixture was estimated by maximum likelihood using an expectation-maximization algorithm (55, 89).

Several computational approaches based on WGS, WES, and TGS data have been used to detect MSI, taking into account the difficulties of microsatellite sequences including management of stutter peak formation induced by PCR amplification during NGS library preparation, sequencing errors induced by homopolymers, and the shortcomings of sequencing read length which limits the length of the microsatellites analyzed (Figure 3)

The first study on colorectal and endometrial cancer described an MSI detection approach using WES and WGS data from The Cancer Genome Atlas (TCGA) (90). This study used mono- to tetra-nucleotide repeat microsatellites identified by
FIGURE 2 | Strategies for improving the limit of detection of MSI in cancer. (A) Dilution of the DNA to 0–3 genome equivalent per PCR in small-pool PCR. (B) Mutant allele enrichment in the DNA sample using sense and antisense probes complementary to WT DNA sequence and duplex specific nuclease (DSN) in NaME-Pro and NaMSIE. (C) Mutant allele enrichment during E-ice-COLD-PCR using an LNA blocker probe complementary to WT DNA sequence. LNA, Locked nucleic acid.
Sputnik (91) to detect unstable microsatellites by comparing their length distribution between tumor and matched normal samples using the Kolmogorov-Smirnov statistic but without proposing a MSI/MSS tumor classifier (56).

Subsequently, different methods were developed for MSI detection in cancer, based on the comparison of the length distribution of a selection of microsatellites obtained by read count of all alleles (Figure 3A). For example, MSIsensor, a method which uses paired tumor and normal WES data to compare the allele length distribution of mono- to pentanucleotide repeat microsatellites, and applies the chi square statistic for each locus analyzed, giving an MSI score that corresponds to the percentage of unstable microsatellite loci with a threshold of 3.5% for the MSI tumor phenotype (29). The second method developed was mSINGs, which uses WES and TGS data to investigate for MSI in 15–2957 mononucleotide repeat microsatellites, and compares the allele length distribution of each microsatellite in the MSI-negative control samples...
(baseline) with that of the tumor samples to detect unstable microsatellites; it uses a Z-score approach and a threshold of 20% of unstable markers to define MSI in tumors (27). This method has notably allowed the detection of MSI in 14 out of 18 types of cancer using TCGA data (17). Another method, MANTIS, uses a set of mono- to penta-nucleotide repeat microsatellites from WES data to detect MSI, by individually computing and aggregating the differences between the allele length distribution of each locus of matched tumor and normal samples to achieve an average distance score (0: fully stable and 2: fully unstable); a score threshold of 0.4 is recommended to diagnose MSI in tumors (28). MANTIS presents a higher overall sensitivity and specificity than MSISensor and mSINGs, and has been used for MSI detection in 39 cancer types from TCGA (18). In a recent study based on WES and WGS data from TCGA, 23 cancer types were analyzed and unstable mono- to tetra-nucleotide repeat microsatellite loci were identified from tumor and normal samples by Kolmogorov-Smirnov statistics; the results were used to build a binary classifier based on the random forest model to predict MSI status (4). Finally, the MSI-ColonCore method was developed based on TCGA data. In this method, the allele length distribution of mononucleotide repeat microsatellites from tumor samples are compared to a baseline formed by normal MSS reference samples using a Z-score approach to predict the MSI status of tumors, which are then classified into three possible groups: MSI/MSI-H, MSI-L, and MSS (48).

Other methods developed for MSI assessment in cancer use a different approach based on the mutation burden in all sequences and/or the burden of indels in microsatellites (Figure 3B). To date, MSI-seq Index is the only MSI detection method that is based on RNA sequencing data and the ratio of two measures, called PI and PD, which correspond to the proportion of insertions and deletions in mono- to hexa-nucleotide repeat microsatellites among all insertions and deletions found in RNA transcripts, respectively (92). When a threshold of 0.9 is applied, the PI/PD ratio is able to distinguish between MSS and MSI tumor samples without the use of matched normal samples (92). The MSI-seq/NGS software offers a classifier for MSI assessment using WES somatic mutation data (small nucleotide substitutions and indels) and based on four machine-learning frameworks (logistic regression, decision tree, random forest, and naïve Bayes) (93). This method uses the rate and ratio of the small nucleotide substitutions in all sequences, and the indels of mono- to tetra-nucleotide repeat microsatellites, to classify the samples into “MSI” and “non-MSI”; it gives the best results with the decision tree classifier (93). Finally, the latest method to be developed uses targeted sequencing data from 275 genes implicated in cancer where the total mutation burden (>40 per Mb) and the indels in mononucleotide microsatellites (>5 per Mb) are used to define tumor samples such as MSI-H (94).

If the main advantage of these NGS based computational methods is that they allow a large number of microsatellite loci to be screened simultaneously, it should be remembered that NGS experiments are much more expensive to perform and require more time to generate results due to the more complex bioinformatics analysis required, and that they give similar or only slightly better sensitivity compared to standard capillary electrophoresis procedures (27, 46, 48).

Among the computational methods for MSI detection in cancer, MSISensor (https://github.com/ding-lab/msisensor, v0.5, last updated on September 18, 2018) (29), mSINGs (https://bitbucket.org/uwlabmed/msings, v3.4, last updated on August 10, 2018) (27), MANTIS (https://github.com/OSU-SRLab/MANTIS, v1.0.4, last updated on June 19, 2018) (28), and MSIseq/NGS classifier (https://CRAN.R-project.org/package=MSIseq, v1.0.0, last updated on June 15, 2015) (93) are available online for download.

**CONCLUSION**

Although the discovery of MSI in cancer is a quarter of a century old, it is relatively recent compared to the discovery of point mutations, epimutations, and copy number variations in cancer. The different methods developed so far for the detection and identification of MSI in cancer are mostly derived from methods created initially for the study of natural variations/polymorphisms present in the human genome or for point mutations present in cancer. These methods still appear to be in their infancy since to date only a small number have been developed for MSI detection, and of these very few are applicable to potential clinical applications of interest such as the detection of MSI in plasma, circulating tumor cells, blood, heterogeneous tumors, or tumors with a high level of normal cell contamination. In contrast, these methods have already been implemented for other types of alterations in cancer.

Numerous difficulties could explain these delays in technological development, notably the high polymorphism levels of microsatellite sequences in the different human populations and the errors induced by PCR slippage during amplification of microsatellite sequences, which increases the complexity not only of the analysis of microsatellite profiles but of the MSI detection and the identification of mutant alleles. More recently, several factors such as the errors induced during the sequencing-by-synthesis of homopolymers by next-generation sequencing, the difficulties of alignment of repetitive DNA sequences due to the short read length, and the low accuracy of indel calling, have also created a computational challenge for MSI detection by NGS-based computational methods, due to the high risk of interparation errors, a problem which requires a longer duration for the development of algorithms.

Given the recent discovery of MSI in dozens of types of cancer, which correlates in a positive dose-effect manner to survival outcome, and the demonstration that MSI is a major predictive biomarker for the efficacy of immune checkpoint blockade therapy in solid tumors, there is undoubtedly a need for the development of new sensitive tools for MSI detection, including clinical applications for MSI diagnosis. Future perspectives should include (i) the development of pan-cancer panels of highly sensitive and specific microsatellite markers for the detection of MSI in cancer, and (ii) the development of combined methods to improve the limit of detection of MSI, as required for certain types of clinical samples (i.e., tumors with high
normal cell contamination, blood, and plasma); the latter could include the enrichment of mutant alleles prior to massively parallel NGS. These methods could then be rapidly implemented in routine clinical applications for the diagnosis of MSI in cancer.

**AUTHOR CONTRIBUTIONS**

LB, J-FD, and AH-K conceived, wrote and approved the final version of the submitted manuscript. AH-K supervised the whole writing of the manuscript.

**REFERENCES**

1. Boland CR, Goel A. Microsatellite instability in colorectal cancer. *Gastroenterology* (2010) 138:2073–87.e3. doi: 10.1053/j.gastro.2009.12.064
2. Thibodeau SN, French AJ, Cunningham JM, Tester D, Burgart LJ, Roche PC, et al. Microsatellite instability in colorectal cancer: different mutator phenotypes and the principal involvement of hmlh1. *Cancer Res.* (1998) 58:1713–8.
3. Pritchard CC, Morrissey C, Kumar A, Zhang X, Smith C, Coleman I, et al. Complex msh2 and msh6 mutations in hypermutated microsatellite unstable advanced prostate cancer. *Nat Commun.* (2014) 5:9888. doi: 10.1038/ncomms9888
4. Cortes-Ciriano I, Lee S, Park WY, Kim TM, Park PJ. A molecular portrait of microsatellite instability across multiple cancers. *Nat Commun.* (2017) 8:15180. doi: 10.1038/ncomms15180
5. Zighelboim I, Goodfellow PJ, Gao F, Gibb RK, Powell MA, Rader JS, et al. Microsatellite instability and epigenetic inactivation of mlh1 and outcome of patients with endometrial cancers of the endometrioid type. *J Clin Oncol.* (2007) 25:2042–8. doi: 10.1200/JCO.2006.08.2107
6. Seo HM, Chang YS, Joo SH, Kim YW, Park YK, Hong SW, et al. Clinicopathologic characteristics and outcomes of gastric cancers with the msi-h phenotype. *J Surg Oncol.* (2009) 99:143–7. doi: 10.1002/jso.21220
7. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. *Science* (1993) 260:816–9. doi: 10.1126/science.8484122
8. Hamelin R, Chalastanis A, Colas C, El Bichri J, Mercier D, Schreurs AS, et al. [Clinical and molecular consequences of microsatellite instability in human cancers]. *Bull Cancer* (2008) 95:121–32. doi: 10.1684/bdc.2008.0531
9. Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colon carcinogenesis. *Nature* (1993) 363:558–61. doi: 10.1038/363558a0
10. Aaltolen LA, Salovaara R, Kristo P, Czanian F, Hemminki A, Peltomaki P, et al. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. *N Eng J Med.* (1998) 338:1481–7. doi: 10.1056/NEJM199805213382101
11. Barnetson RA, Tenesa A, Farrington SM, Nicholl ID, Cetnarsky J, Porteous ME, et al. Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. *N Eng J Med.* (2006) 354:2751–63. doi: 10.1056/NEJMoa053493
12. Lynch HT, de la Chapelle A. Hereditary colorectal cancer. *N Eng J Med.* (2003) 348:919–32. doi: 10.1056/NEJMra022242
13. Wimmer K, Kratz CP, Vasen HF, Caron O, Colas C, Entz-Werle N, et al. Diagnostic criteria for constitutional mismatch repair deficiency syndrome: suggestions of the european consortium 'care for cmmdr' (c=cmmdr). *J Med Genet.* (2014) 51:355–65. doi: 10.1136/jmedgenet-2014-102284
14. Wimmer K, Etzl J. Constitutional mismatch repair-deficiency syndrome: have we so far seen only the tip of an iceberg? *Hum Genet.* (2008) 124:105–22. doi: 10.1007/s00439-008-0542-4
15. Murphy MA, Wentzensen N. Frequency of mismatch repair deficiency in ovarian cancer: a systematic review this article is a us government work and, as such, is in the public domain of the united states of america. *Int J Cancer* (2011) 129:1914–22. doi: 10.1002/ijc.25835
16. Chiappini F, Gross-Goupil M, Saffroy R, Azoulay D, Emile JF, Veilhan LA, et al. Microsatellite instability mutator phenotype in hepatocellular carcinoma in non-alcoholic and non-virally infected normal livers. *Carcinogenesis* (2004) 25:541–7. doi: 10.1093/carcin/bgh035
17. Hause RJ, Pritchard CC, Shendure J, Salipante SJ. Classification and characterization of microsatellite instability across 18 cancer types. *Nat Med.* (2016) 22:1342–50. doi: 10.1038/nm.4191
18. Bonneville R, Krock MA, Kautto EA, Miyia J, Wing MR, Chen HZ, et al. Landscape of microsatellite instability across 39 cancer types. *JCO Prec Oncol.* (2017) 2017. doi: 10.1200/P0.17.00073
19. Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulahlk LK, et al. Mismatch repair deficiency predicts response of solid tumors to pd-1 blockade. *Science* (2017) 357:409–13. doi: 10.1126/science.aam6733
20. Le DT, Uram NJ, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. Pd-1 blockade in tumors with mismatch-repair deficiency. *N Eng J Med.* (2015) 372:2509–20. doi: 10.1056/NEJMoa1500596
21. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, et al. A national cancer institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. *Cancer Res.* (1998) 58:5248–57.
22. Umar A, Boland CR, Tardiman JP, Syngal S, de la Chapelle A, Ruschoff J, et al. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (lymph syndrome) and microsatellite instability. *J Natl Cancer Inst.* (2004) 96:261–8. doi: 10.1093/jnci/djh034
23. Laghi L, Bianchi P, Malesci A. Differences and evolution of the methods for the assessment of microsatellite instability. *Oncogene* (2008) 27:6313–21. doi: 10.1038/onc.2008.217
24. Ladas I, Yu F, Leong KW, Fitarelli-Kiehl M, Song C, Ashtaputre R, et al. Enhanced detection of microsatellite instability using pre-pcr elimination of wild-type DNA homo-polymers in tissue and liquid biopsies. *Nucleic Acids Res.* (2018) 46:e74. doi: 10.1093/nar/gky251
25. Ingham D, Diggle CP, Berry I, Bristow CA, Hayward BE, Rahman N, et al. Simple detection of germline microsatellite instability for diagnosis of constitutional mismatch repair cancer syndrome. *Hum Mutat.* (2013) 34:847–52. doi: 10.1002/humu.23311
26. How-Kit A, Daunay A, Buhard O, Meiller C, Sabbatou M, Collura A, et al. Major improvement in the detection of microsatellite instability in colorectal cancer using hsp110 t7 e-ice-cold-pcr. *Hum Mutat.* (2018) 39:441–53. doi: 10.1002/humu.23379
27. Salipante SJ, Scroggins SM, Hampel HL, Turner EH, Pritchard CC. Microsatellite instability detection by next generation sequencing. *Clin Chem.* (2014) 60:1192–9. doi: 10.1373/clinchem.2014.223677
28. Kautto EA, Bonneville R, Miyia J, Yu L, Krock MA, Reeser JW, et al. Performance evaluation for rapid detection of pan-cancer microsatellite instability with mantis. *Oncotarget* (2017) 8:7452–63. doi: 10.18632/oncotarget.13918
29. Niu B, Ye K, Zhang Q, Lu C, Xie M, McLellan MD, et al. Msisensor: microsatellite instability detection using paired tumor-normal sequence data. *Bioinformatics* (2014) 30:1015–6. doi: 10.1093/bioinformatics/btt755
30. Aaltonen LA, Peltoniemi P, Leach FS, Sistonen P, Pylkkanen L, Mecklin JP, et al. Clues to the pathogenesis of familial colorectal cancer. Science (1993) 260:812–6. doi: 10.1126/science.8484121
31. Welsh J, McClelland M. Fingerprinting genomes using PCR with arbitrary primers. Nucleic Acids Res. (1990) 18:7211–5. doi: 10.1093/nar/18.24.7213
32. Boecker T, Diermeier J, Friedl W, Geberl H, Holinski-Feder E, Karner-Hausch J, et al. Microsatellite instability analysis: a multicenter study for reliability and quality control. Cancer Res. (1997) 57:4739–43.
33. Cawkwell L, Li D, Lewis FA, Martin I, Dixon MF, Quirke P. Microsatellite instability in colorectal cancer: improved assessment using fluorescent polymerase chain reaction. Gastroenterology (1995) 109:465–71. doi: 10.1016/0016-5085(95)90334-8
34. Gan C, Love C, Beshay V, Macrae F, Fox S, Waring P, et al. Application of next generation sequencing technology in microsatellite instability testing. Genes (2015) 6:46–59. doi: 10.3390/genes6010046
35. Zhou L, Huang Y, Fang X, Liu C, Deng W, Zhong C, et al. A novel and reliable method to detect microsatellite instability in colorectal cancer by next-generation sequencing. J Mol Diagn. (2018) 20:225–31. doi: 10.1016/j.jmoldx.2017.11.007
36. Bocker T, Diermeier J, Friedl W, Geberl H, Holinski-Feder E, Karner-Hausch J, et al. Microsatellite instability analysis: a multicenter study for reliability and quality control. Cancer Res. (1997) 57:4739–43.
37. Goel A, Nagasaka T, Hamelin R, Boland CR. An optimized pentaplex PCR protocol for microsatellite instability testing in colorectal cancer: improved assessment using fluorescent polymerase chain reaction. Gastroenterology (1995) 109:465–71. doi: 10.1016/0016-5085(95)90334-8
38. Boecker T, Diermeier J, Friedl W, Geberl H, Holinski-Feder E, Karner-Hausch J, et al. Microsatellite instability analysis: a multicenter study for reliability and quality control. Cancer Res. (1997) 57:4739–43.
39. Cawkwell L, Li D, Lewis FA, Martin I, Dixon MF, Quirke P. Microsatellite instability in colorectal cancer: improved assessment using fluorescent polymerase chain reaction. Gastroenterology (1995) 109:465–71. doi: 10.1016/0016-5085(95)90334-8
40. Gan C, Love C, Beshay V, Macrae F, Fox S, Waring P, et al. Application of next generation sequencing technology in microsatellite instability testing. Genes (2015) 6:46–59. doi: 10.3390/genes6010046
41. Soong R, Anuar D, Liu Y, Eu KW, Han HC, Salto-Tellez M, et al. Denaturing high-performance liquid chromatography. J Hum Genet. (2003) 48:525–30. doi: 10.1007/s10038-003-0070-y
42. Janavicius R, Matiukaite D, Jakubauskas A, Griskevicius L. Microsatellite instability detection by high-resolution melting analysis. J Mol Diagn. (2010) 12:1804–11. doi: 10.1093/jnci/dast070
43. Dietmaier W, Wallinger S, Boecker T, Kullmann F, Fishel R, Ruschoff J. Diagnostic microsatellite instability: definition and correlation with mismatch repair protein expression. Cancer Res. (1997) 57:4749–56.
44. Phipps AL, Limburg PJ, Baron JA, Burnett-Hartman AN, Weisenberger DJ, Laird PW, et al. Association between molecular subtypes of colorectal cancer and patient survival. Gastroenterology (2015) 148:77–82.e7. doi: 10.1053/j.gastro.2014.09.038
45. Lanfo P, Lautonon V, Lahermo P, Esteller M, Guo M, Herman JG, et al. Low-level microsatellite instability in most colorectal carcinomas. Cancer Res. (2002) 62:1166–70.
46. Gonzalez-Garcia I, Moreno V, Navarro M, Marti-Rague J, Marcuello C, Benasco C, et al. Standardized approach for microsatellite instability detection in colorectal carcinomas. J Natl Cancer Inst. (2000) 92:544–9. doi: 10.1093/jnci/92.7.544
47. Kim TM, Laird PW, Park PJ. The landscape of microsatellite instability in colorectal and endometrial cancer genomes. Cell (2013) 155:858–68. doi: 10.1016/j.cell.2013.09.015
48. Laghi L, Bianchi P, Roncalli M, Malesci A, Re: revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer ( Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. (2004) 96:1402–3; author reply 3–4. doi: 10.1093/jnci/djh280
49. Perucchini M. Correspondence re: C.R. Boland et al., a national cancer institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer res., 58: 5248–5257, 1998. Cancer Res. (1999) 59:249–56.
50. Sutter C, Gebert J, Bischoff P, Herfarth C, von Knebel Doeberitz M. Molecular cloning of potential hnpcc patients using a multiplex microsatellite PCR system. Mol Cell Probes (1999) 13:157–65. doi: 10.1016/mcp.1999.0231
Baudrin et al. Methods for Microsatellite Instability Detection

68. Bianchi F, Galizia E, Catalani R, Belvederesi L, Ferretti C, Corradini F, et al. CatS is a mononucleotide marker to identify hnpcc patients. J Mol Diagn. (2009) 11:248–52. doi: 10.2353/jmoldx.2009.080155

69. Findeisen P, Kloos M, Mers S, Sutter C, Woerner SM, Dostmann N, et al. T25 repeat in the 3' untranslated region of the casp2 gene: a sensitive and specific marker for microsatellite instability in colorectal cancer. Cancer Res. (2005) 65:8072–8. doi: 10.1158/0008-5472.CAN-04-1146

70. Dorad C, de Thonel A, Collura A, Marisa L, Svrcek M, Lagrange A, et al. Expression of a mutant hsp110 sensitizes colorectal cancer cells to chemotherapy and improves disease prognosis. Nat Med. (2011) 17:1283–9. doi: 10.1038/j.mast.2013.10.054

71. Buhard O, Lagrange A, Guillox A, Colas C, Chouchene M, Wanherdrick K, et al. Hsp110-117 simplifies and improves the microsatellite instability testing in patients with colorectal cancer. J Med Genet. (2016) 53:377–84. doi: 10.1136/jmedgenet-2015-103518

72. Collura A, Lagrange A, Svrcek M, Marisa L, Buhard O, Guillox A, et al. Patients with colorectal tumors with microsatellite instability and large deletions in hsp110-117 have improved response to 5-fluorouracil-based chemotherapy. Gastroenterology (2014) 146:401–11.e1. doi: 10.1053/j.gastro.2013.10.054

73. Bacher JW, Sievers CK, Albrecht DM, Grimes IC, Weiss JM, Matkowskyj KA, et al. Improved detection of microsatellite instability in early colorectal lesions. PLoS ONE (2015) 10:e0132727. doi: 10.1371/journal.pone.0132727

74. Hampel H, Frankel W, Panescu J, Lockman J, Sotamaa K, Fix D, et al. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res. (2006) 66:7810–7. doi: 10.1158/0008-5472.CAN-06-1114

75. Faulkner RD, Seedhouse CH, Das-Gupta EP, Russell NH. Bat-25 and bat-26, two mononucleotide microsatellites, are not sensitive markers of microsatellite instability in acute myeloid leukaemia. Br J Haematol. (2004) 124:160–5. doi: 10.1046/j.1365-2141.2003.04750.x

76. Pagin A, Zerimech F, Leclerc J, Wacrenier A, Lejeune S, Descarpenries C, et al. Evaluation of a new panel of six mononucleotide repeat markers for the detection of DNA mismatch repair-deficient tumours. Br J Cancer (2013) 108:2079–87. doi: 10.1038/bjc.2013.213

77. Bodo S, Colas C, Buhard O. Collura A, Tinat J, Lavoine N, et al. Diagnosis of constitutional mismatch repair-deficiency syndrome based on microsatellite instability and lymphocyte tolerance to methylating agents. Gastroenterology (2015) 149:1017–29.e3. doi: 10.1053/j.gastro.2015.06.013

78. Felton KE, Gilchrist DM, Andrew SE. Constitutive deficiency in DNA mismatch repair. Clin Genet. (2007) 71:483–98. doi: 10.1111/j.1399-0004.2007.00803.x

79. Coolbaugh-Murphy MI, Xu JP, Ramagli LS, Ramagli BC, Brown BW, Lynch PM, et al. Microsatellite instability in the peripheral blood leukocytes of hnpcc patients. Hum Mutat. (2010) 31:317–24. doi: 10.1002/humu.21190

80. Parsons R, Li GM, Longley M, Modrich P, Liu B, Berk T, et al. Mismatch repair deficiency in phenotypically normal human cells. Science (1995) 268:738–40. doi: 10.1126/science.763227

81. Hu P, Lee CW, Xu JP, Simien C, Fan CL, Tam M, et al. Microsatellite instability in saliva from patients with hereditary non-polyposis colon cancer and siblings carrying germline mismatch repair gene mutations. Ann Clin Lab Sci. (2011) 41:321–30.

82. Baudrin LD, Duval A, Daunay A, Buhard O, Bui H, Deleuze JF, et al. Improved microsatellite instability detection and identification by nucleic-assisted microsatellite instability enrichment using hsp110-117. Clin Chem. (2018) 64:1252–3. doi: 10.1373/clinchem.2018.287490

83. How Kit A, Mazaleyrat N, Daunay A, Nielsen HM, Terris B, Tost J. Sensitive detection of kras mutations using enhanced-ice-cold-pcr mutation enrichment and direct sequence identification. Hum Mutat. (2013) 34:1568–80. doi: 10.1002/humu.22427

84. How-Kit A, Lebbe C, Bousard A, Daunay A, Mazaleyrat N, Daviaud C, et al. Ultrasonis detection and identification of braf v600 mutations in fresh frozen, rife, and plasma samples of melanoma patients by e-ice-cold-pcr. Anal Bioanal Chem. (2014) 406:5513–20. doi: 10.1007/s00216-014-7975-5

85. How Kit-A, Tost J. Pyrosequencing(s)-based identification of low-frequency mutations enriched through enhanced-ice-cold-pcr. Methods Mol Biol. (2015) 1315:83–101. doi: 10.1007/978-1-4939-2715-9_7

86. Mauger F, Daunay A, Deleuze JF, Tost J, How-Kit A. Multiplexing of e-ice-cold-pcr assays for mutation detection and identification. Clin Chem. (2016) 62:1155–8. doi: 10.1373/clinchem.2016.258830

87. Mauger F, How-Kit A, Tost J. Cold-pcr technologies in the area of personalized medicine: methodology and applications. Mol Diagn Ther. (2017) 21:269–83. doi: 10.1007/s10021-016-0254-8

88. Musulen E, Moreno V, Reyes G, Sancho FJ, Peinado MA, Esteller M, et al. Standardized approach for microsatellite instability detection in gastric carcinomas. Hum Pathol. (2004) 35:335–42. doi: 10.1016/j.humpath.2003.10.021

89. Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, Ellrott K, et al. The cancer genome atlas pan-cancer analysis project. Nat Genet. (2013) 45:1113–20. doi: 10.1038/ng.2764

90. Leclercq S, Rivals E, Jarne P. Detecting microsatellites within genomes: significant variation among algorithms. BMC Bioinformatics (2007) 8:125. doi: 10.1186/1471-2105-8-125

91. Lu Y, Soong TD, Elemento O. A novel approach for characterizing microsatellite instability in cancer cells. PLoS ONE (2013) 8:e63056. doi: 10.1371/journal.pone.0063056

92. Huang MN, McPherson JR, Cutcutache I, Teh BT, Tan P, Rozen SG. Msiseq: software for assessing microsatellite instability from catalogs of somatic mutations. Sci Rep. (2015) 5:13321. doi: 10.1038/srep13321

93. Nowak JA, Urgenlb MB, Bruce JL, Rojas-Rudilla V, Hall DL, Shivdasani P, et al. Detection of mismatch repair deficiency and microsatellite instability in colorectal adenocarcinoma by targeted next-generation sequencing. J Mol Diagn. (2017) 19:84–91. doi: 10.1016/j.jmoldx.2016.07.010

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Baudrin, Deleuze and How-Kit. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.